DARA BioSciences, Inc. (DARA)

[macjockey]

Valid feedback. However, it's worth noting that many factors have changed since then. Sales are up based on an outbound sales team initiative that has the last two quarters up 400-600% year over growth. The FDA has issued waivers for 1.1 million dollars in fees paid for KRN that they are now refunding based on its promise. The drug also has a double orphan designation. Based on the fact that the stock is essentially trading at nothing but cash value, and the cash value just increased by 8% based purely on the waivers, and the sales growth appears on a pretty extreme upward trend, this company could be profitable by the end of the year. This doesn't account for a highly likely partnership announcement that could add 10-20 million dollars to their cash pile to fund operations and KRN clinical trials. That announcement alone would have the company trading at 2.00 per share just at a cash valuation alone. Once the KRN drug is priced in, the upside to this stock is radical.

The company has until May to establish Nasdaq compliance at over 1.00 valuation for ten concurrent days before needing to evaluate a Reverse Split. The likelihood that no announcement takes place between now and then is extremely low. In all recent presentations, the company is projected to announce both FDA roadmap for KRN drug approval, and a partnership "In early 2015." This was as recent as two weeks ago at an investor presentation in San Francisco.

In December the company issued an 8K detailing some moves with purchasing outstanding stock that is anticipated to be greasing the way forward for their KRN partnership as one of the last pieces outstanding. It is my opinion (as well as the opinion of Daniel Ward with Seeking Alpha) that this is an investment primed to make some massive gains in the next 2-8 weeks.